Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab.
Wistuba-Hamprecht K, Martens A, Haehnel K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Demuth I, Steinhagen-Thiessen E, Larbi A, Schilling B, Schadendorf D, Wolchok JD, Blank CU, Pawelec G, Garbe C, Weide B.
Wistuba-Hamprecht K, et al.
Eur J Cancer. 2016 Sep;64:116-26. doi: 10.1016/j.ejca.2016.06.001. Epub 2016 Jul 9.
Eur J Cancer. 2016.
PMID: 27400322
Free PMC article.